Redox Signaling in Physiological and Pathological Conditions

Dear Colleagues,

Reactive oxygen species (ROS) and reactive nitrogen species (RNS), which are usually generated by tightly regulated enzymes, are well recognized for playing a dual role as both beneficial and deleterious species. These molecules have recently been involved in a multiplicity of physiological responses through the modulation of numerous cellular pathways. At low or moderate amounts, they play a key role in the modulation of essential cellular processes for the cells, such as cell cycle regulation, differentiation, growth, and cellular metabolism. However, a pathologically high level of oxidant species in cells (due to either an overproduction of ROS or alterations in antioxidant systems), i.e., the formation of ROS, is a deleterious process that can mediate damage to cell structures, including lipids, proteins, and DNA. This process, which have been called oxidative stress, seems to have an important role in various disease states, such as tumorigenesis, autoimmunity, neurodegenerative diseases, and loss of tissue regeneration. In fact, this “two-faced” characteristic of ROS is clearly observed in cancer. A growing body of evidence shows that ROS act as secondary messengers in intracellular signaling cascades, which induce and maintain the oncogenic phenotype of cancer cells. However, ROS can also induce cellular senescence and apoptosis and can therefore act as anti-tumorigenic species.

This Special Issue welcomes original papers and reviews on any relevant aspect of redox biology in physiological as well as pathological conditions: how these ROS and RNS can modulate important cellular pathways related to essential processes for cells; what role they play in physiological processes, such as growth, differentiation, or metabolism; how they promote different disease states, such as tumorigenesis, autoimmunity, and neurodegenerative diseases; and any aspect related to ROS pathology. New therapeutic approaches related to ROS signaling and/or aimed at restoring the levels of these mediators (through antioxidant supplementation) in any pathology will be also considered.

Prof. Ana Clara Carrera
Dr. Antonio Garrido
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• oxidant compounds
• oxidative stress
• inflammation
• autoimmunity
• neurodegenerative diseases
• cancer
• tumorigenesis
• tissue repair
• ROS metabolism
• immunomodulation
• antioxidant strategies